中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 37 Issue 1
Jan.  2021
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2021  >  37(1): 188-191

The role and mechanism of invariant natural killer T cells in liver anti-tumor immunity

DOI: 10.3969/j.issn.1001-5256.2021.01.041

  • Department of Hepatopathy and Cancer Biotherapy, Beijing YouAn Hospital, Capital Medical University, Beijing 100069, China

  • Received Date: 2020-05-20
  • Accepted Date: 2020-08-31
  • Published Date: 2021-01-20
    Abstract
  • Invariant natural killer T (iNKT) cells are a T lymphocyte subset derived from the thymus and can express both natural killer cell-related receptors and T cell receptor. The iNKT cells are widely distributed in the body and are enriched in the liver, and they exhibit unique functional characteristics and can secrete cytokines and regulate the activity of other immune cells in microenvironment, so as to achieve the role of immune surveillance and disease prevention; especially in tumor microenvironment, iNKT cells can stimulate anti-tumor immune response and reverse immunosuppressive microenvironment in the liver. This article reviews the biological characteristics of iNKT cells and their special role in liver immune homeostasis, especially the anti-tumor effect and mechanism of iNKT cells.

     

    • FullText(HTML)
  • loading
    • References(43)
  • [1]
    BENDELAC A, SAVAGE PB, TEYTON L. The biology of NKT cells[J]. Annu Rev Immunol, 2007, 25: 297-336. DOI: 10.1146/annurev.immunol.25.022106.141711
    [2]
    ZHANG Y, SPRINGFIELD R, CHEN S, et al. Alpha-galcer and iNKT cell-based cancer immunotherapy: Realizing the therapeutic potentials[J]. Front Immunol, 2019, 10: 1126. DOI: 10.3389/fimmu.2019.01126
    [3]
    BROSSAY L, CHIODA M, BURDIN N, et al. CD1d-mediated recognition of an alpha-galactosylceramide by natural killer T cells is highly conserved through mammalian evolution[J]. J Exp Med, 1998, 188(8): 1521-1528. DOI: 10.1084/jem.188.8.1521
    [4]
    MORENO M, MOL BM, von MENSDORFF-POUILLY S, et al. Differential indirect activation of human invariant natural killer T cells by Toll-like receptor agonists[J]. Immunotherapy, 2009, 1(4): 557-570.
    [5]
    KITAMURA H, IWAKABE K, YAHATA T, et al. The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells[J]. J Exp Med, 1999, 189(7): 1121-1128. DOI: 10.1084/jem.189.7.1121
    [6]
    NAIR S, DHODAPKAR MV. Natural killer T cells in cancer immunotherapy[J]. Front Immunol, 2017, 8: 1178. DOI: 10.3389/fimmu.2017.01178
    [7]
    GANSUVD B, HAGIHARA M, YU Y, et al. Human umbilical cord blood NK T cells kill tumors by multiple cytotoxic mechanisms[J]. Hum Immunol, 2002, 63(3): 164-175. DOI: 10.1016/S0198-8859(01)00382-2
    [8]
    CAMERON G, GODFREY DI. Differential surface phenotype and context-dependent reactivity of functionally diverse NKT cells[J]. Immunol Cell Biol, 2018.[Online ahead of print]
    [9]
    EBERL G, LEES R, SMILEY ST, et al. Tissue-specific segregation of CD1d-dependent and CD1d-independent NK T cells[J]. J Immunol, 1999, 162(11): 6410-6419.
    [10]
    LEE YJ, WANG H, STARRETT GJ, et al. Tissue-specific distribution of iNKT cells impacts their cytokine response[J]. Immunity, 2015, 43(3): 566-578. DOI: 10.1016/j.immuni.2015.06.025
    [11]
    KIM CH, JOHNSTON B, BUTCHER EC. Trafficking machinery of NKT cells: Shared and differential chemokine receptor expression among V alpha 24(+)V beta 11(+) NKT cell subsets with distinct cytokine-producing capacity[J]. Blood, 2002, 100(1): 11-16. DOI: 10.1182/blood-2001-12-0196
    [12]
    JOHNSTON B, KIM CH, SOLER D, et al. Differential chemokine responses and homing patterns of murine TCR alpha beta NKT cell subsets[J]. J Immunol, 2003, 171(6): 2960-2969. DOI: 10.4049/jimmunol.171.6.2960
    [13]
    THOMAS SY, HOU R, BOYSON JE, et al. CD1d-restricted NKT cells express a chemokine receptor profile indicative of Th1-type inflammatory homing cells[J]. J Immunol, 2003, 171(5): 2571-2580. DOI: 10.4049/jimmunol.171.5.2571
    [14]
    BANDYOPADHYAY K, MARRERO I, KUMAR V. NKT cell subsets as key participants in liver physiology and pathology[J]. Cell Mol Immunol, 2016, 13(3): 337-346. DOI: 10.1038/cmi.2015.115
    [15]
    RACANELLI V, REHERMANN B. The liver as an immunological organ[J]. Hepatology, 2006, 43(2 Suppl 1): s54-s62.
    [16]
    WISSE E. An electron microscopic study of the fenestrated endothelial lining of rat liver sinusoids[J]. J Ultrastruct Res, 1970, 31(1): 125-150.
    [17]
    GEISSMANN F, CAMERON TO, SIDOBRE S, et al. Intravascular immune surveillance by CXCR6+ NKT cells patrolling liver sinusoids[J]. PLoS Biol, 2005, 3(4): e113. DOI: 10.1371/journal.pbio.0030113
    [18]
    KEE JY, ITO A, HOJO S, et al. Chemokine CXCL16 suppresses liver metastasis of colorectal cancer via augmentation of tumor-infiltrating natural killer T cells in a murine model[J]. Oncol Rep, 2013, 29(3): 975-982. DOI: 10.3892/or.2012.2185
    [19]
    KUBES P, JENNE C. Immune responses in the liver[J]. Annu Rev Immunol, 2018, 36: 247-277. DOI: 10.1146/annurev-immunol-051116-052415
    [20]
    JACOB AI, GOLDBERG PK, BLOOM N, et al. Endotoxin and bacteria in portal blood[J]. Gastroenterology, 1977, 72(6): 1268-1270. DOI: 10.1016/S0016-5085(77)80025-5
    [21]
    DOHERTY DG. Immunity, tolerance and autoimmunity in the liver: A comprehensive review[J]. J Autoimmun, 2016, 66: 60-75. DOI: 10.1016/j.jaut.2015.08.020
    [22]
    SINGH AK, GAUR P, DAS SN. Natural killer T cell anergy, co-stimulatory molecules and immunotherapeutic interventions[J]. Hum Immunol, 2014, 75(3): 250-260. DOI: 10.1016/j.humimm.2013.12.004
    [23]
    JIANG X, SHIMAOKA T, KOJO S, et al. Cutting edge: Critical role of CXCL16/CXCR6 in NKT cell trafficking in allograft tolerance[J]. J Immunol, 2005, 175(4): 2051-2055. DOI: 10.4049/jimmunol.175.4.2051
    [24]
    HUANG W, HE W, SHI X, et al. The role of CD1d and MR1 restricted T cells in the liver[J]. Front Immunol, 2018, 9: 2424. DOI: 10.3389/fimmu.2018.02424
    [25]
    KANEKO Y, HARADA M, KAWANO T, et al. Augmentation of Valpha14 NKT cell-mediated cytotoxicity by interleukin 4 in an autocrine mechanism resulting in the development of concanavalin A-induced hepatitis[J]. J Exp Med, 2000, 191(1): 105-114. DOI: 10.1084/jem.191.1.105
    [26]
    ZHU S, ZHANG H, BAI L. NKT cells in liver diseases[J]. Front Med, 2018, 12(3): 249-261. DOI: 10.1007/s11684-018-0622-3
    [27]
    MARICIC I, SHENG H, MARRERO I, et al. Inhibition of type I natural killer T cells by retinoids or following sulfatide-mediated activation of type Ⅱ natural killer T cells attenuates alcoholic liver disease in mice[J]. Hepatology, 2015, 61(4): 1357-1369. DOI: 10.1002/hep.27632
    [28]
    KAKIMI K, GUIDOTTI LG, KOEZUKA Y, et al. Natural killer T cell activation inhibits hepatitis B virus replication in vivo[J]. J Exp Med, 2000, 192(7): 921-930. DOI: 10.1084/jem.192.7.921
    [29]
    YE L, WANG X, WANG S, et al. CD56+ T cells inhibit hepatitis C virus replication in human hepatocytes[J]. Hepatology, 2009, 49(3): 753-762. DOI: 10.1002/hep.22715
    [30]
    ZAHRAN AM, ABDEL-MEGUID MM, ASHMAWY AM, et al. Frequency and implications of natural killer and natural killer T cells in hepatocellular carcinoma[J]. Egypt J Immunol, 2018, 25(2): 45-52.
    [31]
    KENNA T, GOLDEN-MASON L, PORCELLI SA, et al. NKT cells from normal and tumor-bearing human livers are phenotypically and functionally distinct from murine NKT cells[J]. J Immunol, 2003, 171(4): 1775-1779. DOI: 10.4049/jimmunol.171.4.1775
    [32]
    XIAO YS, GAO Q, XU XN, et al. Combination of intratumoral invariant natural killer T cells and interferon-gamma is associated with prognosis of hepatocellular carcinoma after curative resection[J]. PLoS One, 2013, 8(8): e70345. DOI: 10.1371/journal.pone.0070345
    [33]
    MIYAGI T, TAKEHARA T, TATSUMI T, et al. CD1d-mediated stimulation of natural killer T cells selectively activates hepatic natural killer cells to eliminate experimentally disseminated hepatoma cells in murine liver[J]. Int J Cancer, 2003, 106(1): 81-89. DOI: 10.1002/ijc.11163
    [34]
    YANAGISAWA K, SEINO K, ISHIKAWA Y, et al. Impaired proliferative response of V alpha 24 NKT cells from cancer patients against alpha-galactosylceramide[J]. J Immunol, 2002, 168(12): 6494-6499. DOI: 10.4049/jimmunol.168.12.6494
    [35]
    MARGALIT M, SHIBOLET O, KLEIN A, et al. Suppression of hepatocellular carcinoma by transplantation of ex-vivo immune-modulated NKT lymphocytes[J]. Int J Cancer, 2005, 115(3): 443-449. DOI: 10.1002/ijc.20889
    [36]
    BAE EA, SEO H, KIM IK, et al. Roles of NKT cells in cancer immunotherapy[J]. Arch Pharm Res, 2019, 42(7): 543-548. DOI: 10.1007/s12272-019-01139-8
    [37]
    FU Y, LIU S, ZENG S, et al. From bench to bed: the tumor immune microenvironment and current immunotherapeutic strategies for hepatocellular carcinoma[J]. J Exp Clin Cancer Res, 2019, 38(1): 396. DOI: 10.1186/s13046-019-1396-4
    [38]
    GEBREMESKEL S, CLATTENBURG DR, SLAUENWHITE D, et al. Natural killer T cell activation overcomes immunosuppression to enhance clearance of postsurgical breast cancer metastasis in mice[J]. Oncoimmunology, 2015, 4(3): e995562. DOI: 10.1080/2162402X.2014.995562
    [39]
    KO HJ, LEE JM, KIM YJ, et al. Immunosuppressive myeloid-derived suppressor cells can be converted into immunogenic APCs with the help of activated NKT cells: An alternative cell-based antitumor vaccine[J]. J Immunol, 2009, 182(4): 1818-1828. DOI: 10.4049/jimmunol.0802430
    [40]
    HIX LM, SHI YH, BRUTKIEWICZ RR, et al. CD1d-expressing breast cancer cells modulate NKT cell-mediated antitumor immunity in a murine model of breast cancer metastasis[J]. PLoS One, 2011, 6(6): e20702. DOI: 10.1371/journal.pone.0020702
    [41]
    BAE EA, SEO H, KIM BS, et al. Activation of NKT cells in an anti-PD-1-resistant tumor model enhances antitumor immunity by reinvigorating exhausted CD8 T cells[J]. Cancer Res, 2018, 78(18): 5315-5326. DOI: 10.1158/0008-5472.CAN-18-0734
    [42]
    HECZEY A, LIU D, TIAN G, et al. Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy[J]. Blood, 2014, 124(18): 2824-2833. DOI: 10.1182/blood-2013-11-541235
    [43]
    YONG CSM, DARDALHON V, DEVAUD C, et al. CAR T-cell therapy of solid tumors[J]. Immunol Cell Biol, 2017, 95(4): 356-363. DOI: 10.1038/icb.2016.128
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (528) PDF downloads(70) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return